Cargando…

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms

Detalles Bibliográficos
Autores principales:	Hasselbalch, Hans C., Silver, Richard T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601345/ https://www.ncbi.nlm.nih.gov/pubmed/34805764 http://dx.doi.org/10.1097/HS9.0000000000000645

Ejemplares similares

The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
por: Yoon, Seug Yun, et al.
Publicado: (2021)

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms
por: Liisborg, Charlotte, et al.
Publicado: (2020)

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms
por: Holmström, Morten Orebo, et al.
Publicado: (2020)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
por: Campregher, Paulo Vidal, et al.
Publicado: (2012)

Inflammatory picture of Philadelphia-negative myeloproliferative neoplasms()
por: Pagnano, Katia Borgia Barbosa
Publicado: (2018)

Effects of Mutational Combinations on Philadelphia-Negative Myeloproliferative Neoplasms
por: Ipek, Yonal-Hindilerden, et al.
Publicado: (2017)

Philadelphia‐negative myeloproliferative neoplasms among Kuwaiti Nationals
por: Alshemmari, Salem, et al.
Publicado: (2020)

Splenic Infarction in Patients with Philadelphia-negative Myeloproliferative Neoplasms
por: Lee, Myung-Won, et al.
Publicado: (2022)

Applications of Artificial Intelligence in Philadelphia-Negative Myeloproliferative Neoplasms
por: Elsayed, Basel, et al.
Publicado: (2023)

The Role of Neutrophilic Granulocytes in Philadelphia Chromosome Negative Myeloproliferative Neoplasms
por: Kiem, Dominik, et al.
Publicado: (2021)

Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark
por: Brochmann, Nana, et al.
Publicado: (2018)

Mediators of Inflammation in Myeloproliferative Neoplasms: State of the Art
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Chronic Myeloproliferative Neoplasms: Some Remaining Challenges
por: Mughal, Tariq I., et al.
Publicado: (2018)

Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms
por: Benedetti, Edoardo, et al.
Publicado: (2020)

Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms
por: Kaplan, Jason B., et al.
Publicado: (2016)

Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation
por: Cacemiro, Maira da Costa, et al.
Publicado: (2018)

Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic
por: Barbui, Tiziano, et al.
Publicado: (2021)

The Prognostic Role of Cytogenetics Analysis in Philadelphia Negative Myeloproliferative Neoplasms
por: Lanzarone, Giuseppe, et al.
Publicado: (2021)

Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms
por: Stuckey, Ruth, et al.
Publicado: (2023)

Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
por: Hasselbalch, Hans, et al.
Publicado: (2022)

Circulating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic Interest
por: Mondet, Julie, et al.
Publicado: (2015)

Erratum on “Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation”
por: Cacemiro, Maira da Costa, et al.
Publicado: (2021)

Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms
por: Mora, Barbara, et al.
Publicado: (2022)

The Genomic Landscape in Philadelphia-Negative Myeloproliferative Neoplasm Patients with Second Cancers
por: Hsu, Chia-Chen, et al.
Publicado: (2022)

Acquired von willebrand syndrome in patients with Philadelphia-negative myeloproliferative neoplasm
por: Song, Ik-Chan, et al.
Publicado: (2023)

Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review
por: Di Battista, Valeria, et al.
Publicado: (2021)

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios
por: Palandri, Francesca, et al.
Publicado: (2021)

Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms
por: Pandey, Ruchi, et al.
Publicado: (2015)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
por: Helbig, Grzegorz
Publicado: (2018)

Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm
por: Song, Ik-Chan, et al.
Publicado: (2022)

CCL2 rs1024611Gene Polymorphism in Philadelphia-Negative Myeloproliferative Neoplasms
por: Hodeib, Hossam, et al.
Publicado: (2022)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

P1020: SCREENING FOR PORTAL HYPERTENSION IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Davidson, M., et al.
Publicado: (2022)

Philadelphia-negative myeloproliferative neoplasms display alterations in monocyte subpopulations frequency and immunophenotype
por: Bassan, Vitor Leonardo, et al.
Publicado: (2022)

Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need?
por: Mughal, Tariq I., et al.
Publicado: (2019)

Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α
por: Aruna,, et al.
Publicado: (2018)

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
por: Barosi, Giovanni, et al.
Publicado: (2023)

Bcl‐xL represents a therapeutic target in Philadelphia negative myeloproliferative neoplasms
por: Petiti, Jessica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qleu4ttmeo1fa2guu6s5derghq